Clinical Trials Results
|
Results for the search you initiated will be displayed below.
-
Click here for details...
This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy
versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung
cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cisplatin,
pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to
stop the growth of tumor cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. The purpose of this trial is to find out if the addition
of pembrolizumab to usual chemotherapy is better or worse than usual chemotherapy alone for
non-small cell lung cancer.
-
Click here for details...
This phase II/III trial compares the addition of radiation therapy to the usual treatment
(immunotherapy with or without chemotherapy) vs. usual treatment alone in treating patients
with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (advanced) or
has spread to other places in the body (metastatic) whose tumor is also negative for a
molecular marker called PD-L1. Stereotactic body radiation therapy (SBRT) is a type of
radiation therapy that uses high energy x-rays to kill tumor cells and shrink tumors. This
method uses special equipment to position a patient and precisely deliver radiation to tumors
with fewer doses over a shorter period and may cause less damage to normal tissue than
conventional radiation therapy. Immunotherapy with monoclonal antibodies, such as nivolumab,
ipilimumab and pembrolizumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as
carboplatin, pemetrexed, paclitaxel and nab-paclitaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. The addition of radiation therapy to usual treatment may stop
the cancer from growing and increase the life of patients with advanced non-small cell lung
cancer who are PD-L1 negative.
-
Click here for details...
This phase II trial compares the usual treatment alone to using immunotherapy (atezolizumab)
plus the usual treatment in treating patients with peritoneal mesothelioma. The usual
treatment consists of surgery or chemotherapy. Chemotherapy drugs, such as carboplatin and
pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is a
monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.
-
Click here for details...
This phase III ALCHEMIST trial studies genetic testing in screening patients with stage
IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the
genes in a patient's tumor cells may help doctors select the best treatment for patients that
have certain genetic changes.
-
Click here for details...
This trial studies the side effects of pembrolizumab with or without chemotherapy in treating
patients with stage IV non-small cell lung cancer that has come back (recurrent) and has
spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such
as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed
and carboplatin, work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
pembrolizumab with or without chemotherapy may shrink the tumor in older patients with
non-small cell lung cancer.
-
Click here for details...
This phase II trial studies how well osimertinib works in treating patients with non-small
cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back.
Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth.
-
Click here for details...
This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed
by pemetrexed and carboplatin with or without pembrolizumab after disease progression is
superior to induction with pembrolizumab, pemetrexed and carboplatin followed by
pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous
non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab,
may help the body's immune system attack the cancer, and may interfere with the ability of
tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and
carboplatin, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. It is not yet
known whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or
without pembrolizumab works better in treating patients with non-squamous non-small cell
cancer.
-
Click here for details...
This phase III trial studies how well an antibody (durvalumab) with chemotherapy and
radiation therapy (chemoradiation) works in treating patients with stage III non-small cell
lung cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal
antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. This study is being done to see
if adding durvalumab to standard chemoradiation followed by additional durvalumab can extend
patients life and/or prevent the tumor from coming back compared to the usual approach of
chemoradiation alone followed by durvalumab.
-
Click here for details...
This phase III trial compares the effect of bevacizumab and AZD9291 (osimertinib) combination
vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside
of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR
protein is involved in cell signaling pathways that control cell division and survival.
Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal
amounts on some types of cancer cells. This causes cancer cells to divide more rapidly.
Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell
growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with
the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may
control cancer for longer and help patients live longer as compared to osimertinib alone.
-
Click here for details...
This phase II trial compares cabozantinib alone and the combination of cabozantinib and
nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small
cell lung cancer (NSCLC). Cabozantinib may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may
interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as
docetaxel, gemcitabine hydrochloride, paclitaxel, and nab-paclitaxel, work in different ways
to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving cabozantinib alone or in combination
with nivolumab may be more effective than standard chemotherapy in treating patients with
non-small cell lung cancer.
-
Click here for details...
This phase II MATCH trial studies how well treatment that is directed by genetic testing
works in patients with solid tumors or lymphomas that have progressed following at least one
line of standard treatment or for which no agreed upon treatment approach exists. Genetic
tests look at the unique genetic material (genes) of patients' tumor cells. Patients with
genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more
from treatment which targets their tumor's particular genetic abnormality. Identifying these
genetic abnormalities first may help doctors plan better treatment for patients with solid
tumors, lymphomas, or multiple myeloma.
-
Click here for details...
This randomized phase II/III trial studies how well giving maintenance chemotherapy with or
without local consolidation therapy works in treating patients with stage IV non-small cell
lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium,
erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Local consolidation therapy such as radiation/stereotactic body radiation or
surgery may kill cancer cells left after initial treatment. Giving maintenance chemotherapy
and local consolidation therapy together may work better than maintenance chemotherapy alone
in treating patients with stage IV non-small cell lung cancer.
-
Click here for details...
This phase II/III trial compares the effect of adding radiation therapy to the usual
maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already
received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has
spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy
with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack
the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation
therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation
therapy in addition to atezolizumab may extend the time without extensive small cell lung
cancer growing or spreading compared to atezolizumab alone.
-
Click here for details...
This phase II/III Lung-MAP trial studies how well immunotherapy treatment with N-803
(ALT-803) and pembrolizumab working in treating patients with non-small cell lung cancer that
has spread to other places in the body (advanced). Natural killer cells, part of our immune
system, are always on alert and ready to defend our bodies from many kinds of infection or
rogue cells, such as those that cause cancer. N-803 (ALT-803) may activate natural killer
cells so that they can stimulate an immune response to help fight cancer. Immunotherapy with
monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Giving N-803
(ALT-803) and pembrolizumab may help shrink and stabilize lung cancer or prevent it from
returning.
-
Click here for details...
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic
cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in
treating patients with small cell lung cancer. MRI scans are used to monitor the possible
spread of the cancer with an MRI machine over time. PCI is radiation therapy that is
delivered to the brain in hopes of preventing spread of cancer into the brain. The use of
brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan.
Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer)
may be at least as good as the combination of PCI with MRI scans.
-
Click here for details...
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with
genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV
non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth.
-
Click here for details...
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous
non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific
mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to
grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth
of tumor cells.
-
Click here for details...
This phase II Lung-MAP treatment trial tests whether carboplatin and pemetrexed with or
without selpercatinib works to shrink tumors in patients with RET fusion-positive non-small
cell lung cancer that is stage IV or has not responded to previous RET directed therapy.
Chemotherapy drugs, such as carboplatin and pemetrexed, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Selpercatinib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. Giving selpercatinib in combination with
carboplatin and pemetrexed may help lower the chance of the cancer growing and spreading.
-
Click here for details...
This trial studies how well atezolizumab added to the usual radiation therapy works in
treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal
antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread. Radiation therapy, such as
stereotactic body radiation therapy, uses special equipment to position a patient and deliver
radiation to tumors with high precision. This method can kill tumor cells with fewer doses
over a shorter period and cause less damage to normal tissue. Giving atezolizumab and
radiation therapy may work better than radiation therapy alone in treating patients with
early non-small cell lung cancer.
-
Click here for details...
This trial studies the side effects of radiation therapy followed by atezolizumab in treating
patients with stage II or III non-small cell lung cancer. Hyperfractionated radiation therapy
delivers smaller doses of radiation therapy over time and may kill more tumor cells and have
fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help
the body's immune system attack the cancer, and may interfere with the ability of tumor cells
to grow and spread. The purpose of this study is to test the safety and effectiveness of
radiation therapy followed by atezolizumab and find out what side effects, if any, it has on
patient's non-small cell lung cancer.
-
Click here for details...
This phase II trial studies the effect of atezolizumab given with usual chemotherapy during
radiation therapy in treating patients with superior sulcus non-small cell lung cancer.
Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Chemotherapy drugs, such as cisplatin, carboplatin, etoposide, paclitaxel and
pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy
uses high energy beams to kill tumor cells and shrink tumors. Giving atezolizumab with usual
chemotherapy and radiation therapy may lower the chance of the tumor from growing or
spreading.
-
Click here for details...
This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination
with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide
versus standard therapy alone for the treatment of poorly differentiated extrapulmonary
(originated outside the lung) small cell neuroendocrine cancer. The other aim of this trial
is to compare using atezolizumab just at the beginning of treatment versus continuing it
beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab,
may help the body's immune system attack the cancer, and may interfere with the ability of
tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known
as platinum-containing compounds that work by killing, stopping or slowing the growth of
cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It
blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer
cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and
etoposide may work better in treating patients with poorly differentiated extrapulmonary
small cell neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin
or carboplatin) and etoposide alone.
|
